10-K: Breeze Holdings Acquisition Corp. Faces Going Concern Uncertainty Amid Business Combination Pursuit

Breeze Holdings Acquisition Corp.'s 10-K filing reveals a company navigating financial uncertainties as it seeks a business combination, with a looming deadline and reliance on sponsor support.

Summary

• Breeze Holdings Acquisition Corp., a blank check company, is seeking a business combination but faces a June 26, 2025 deadline.
• The company's financial statements for the year ended December 31, 2024, indicate a net loss of $2,304,638 and a working capital deficit of $17,358,530.
• The company's ability to continue as a going concern is dependent on completing a business combination.
• The company relies on its sponsor for financial support, including loans to cover operating costs and extension payments.
• The company has entered into a Merger Agreement with YD Biopharma Limited, with an expected closing in April 2025, but the deal is subject to customary closing conditions and approvals.
• The company has identified a material weakness in its internal control over financial reporting related to income taxes.
• The company's securities are now trading on the OTCQX Best Market under the symbols 'BRZH', 'BRZHW', and 'BRZHR' after being delisted from NASDAQ.
• The company has a limited operating history and has not generated any operating revenues to date.

Sentiment

Score: 3

Explanation: The document presents a mixed picture, with the pursuit of a business combination balanced against financial challenges and a going concern uncertainty. The delisting from NASDAQ and reliance on sponsor support further contribute to a negative sentiment.

Positives

• The company is pursuing a business combination with YD Biopharma Limited, expected to close in April 2025.
• The company has the option to extend the business combination deadline to June 26, 2025.
• The company has a sponsor who has agreed to provide financial support, including loans to cover operating costs and extension payments.

Negatives

• The company reports a net loss of $2,304,638 for the year ended December 31, 2024.
• The company's working capital deficit stands at $17,358,530 as of December 31, 2024.
• The company's ability to continue as a going concern is dependent on completing a business combination by June 26, 2025.
• The company has identified a material weakness in its internal control over financial reporting related to income taxes.
• The company's securities are now trading on the OTCQX Best Market under the symbols 'BRZH', 'BRZHW', and 'BRZHR' after being delisted from NASDAQ.

Risks

• The company may be unable to complete the business combination with YD Biopharma Limited.
• The company may be unable to obtain additional financing to cover operating costs and transaction expenses.
• The company may be unable to address the material weakness in its internal control over financial reporting.
• The company may be unable to generate sufficient revenue to sustain operations after the business combination.
• Geopolitical conflicts and wars may impact the company's ability to complete a business combination.
• The company's reliance on the sponsor for financial support may not be sufficient to cover all expenses.
• The company's securities are now trading on the OTCQX Best Market under the symbols 'BRZH', 'BRZHW', and 'BRZHR' after being delisted from NASDAQ.

Future Outlook

The company is focused on completing a business combination with YD Biopharma Limited, expected to close in April 2025, but faces a June 26, 2025 deadline to complete a business combination.

Industry Context

The document reflects the challenges faced by SPACs in finding and closing deals within specified timeframes, particularly given market volatility and regulatory scrutiny. The delisting from NASDAQ and subsequent trading on OTCQX highlight the difficulties some SPACs encounter in maintaining listing requirements.

Comparison to Industry Standards

• Given the limited information provided, a direct comparison to industry standards is challenging.
• However, the company's financial metrics and operational status can be benchmarked against other SPACs with similar timelines and deal sizes.
• For example, comparable companies include other SPACs that have recently announced or terminated merger agreements, or those that have transitioned to the OTC market.
• Specific metrics to compare include cash burn rate, deal termination fees, and the percentage of shareholders electing to redeem their shares.

Related Party Transactions

• The company has entered into an agreement with an affiliate of the sponsor for office space, utilities, and administrative support services.
• The company has received loans from the sponsor to cover operating costs and extension payments.
• The company may reimburse the sponsor, officers, and directors for out-of-pocket expenses incurred in connection with identifying and completing a business combination.

Stakeholder Impact

• Shareholders face uncertainty regarding the completion of a business combination and the value of their investment.
• Employees of the target business face uncertainty regarding their future employment.
• Creditors face the risk of not being repaid if the company is unable to complete a business combination and is forced to liquidate.

Next Steps

• The company needs to obtain stockholder approval for the business combination with YD Biopharma Limited.
• The company needs to satisfy the closing conditions for the business combination with YD Biopharma Limited.
• The company needs to secure additional financing to cover operating costs and transaction expenses.
• The company needs to address the material weakness in its internal control over financial reporting.

Key Dates